Chapter 51. Management of Waldenstrom's Macroglobulinemia

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Christine I. Chen MD, MMED, FRCP

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch51

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Chen, C. I. (2008) Management of Waldenstrom's Macroglobulinemia, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch51

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857



  • Waldenstrom's macroglobulinemia (WM) - rare B-cell lymphoproliferative disorder;
  • Waldenstrom's macroglobulinemia;
  • best initial treatment for symptomatic patients;
  • combination therapies;
  • Rituximab activity in patients relapsed or refractory to fludarabine;
  • plasmapheresis - urgent adjunct therapy for patients with symptomatic hyperviscosity (Grade 1C);
  • plasmapheresis - adjunct therapy in uncommon antibody-mediated complications of WM


This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusions

  • When should therapy be initiated?

  • What is the best initial treatment for symptomatic patients?

  • What treatment options exist for a patient who has relapsed after initial therapy with fludarabine?

  • What are the indications for plasmapheresis?

  • References